Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) Gross Margin (2021 - 2025)

Historic Gross Margin for Tg Therapeutics (TGTX) over the last 5 years, with Q3 2025 value amounting to 82.63%.

  • Tg Therapeutics' Gross Margin fell 62400.0% to 82.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 85.34%, marking a year-over-year decrease of 29700.0%. This contributed to the annual value of 88.3% for FY2024, which is 56500.0% down from last year.
  • Per Tg Therapeutics' latest filing, its Gross Margin stood at 82.63% for Q3 2025, which was down 62400.0% from 86.58% recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Gross Margin peaked at 97.88% during Q3 2023, and registered a low of 82.14% during Q4 2023.
  • Its 5-year average for Gross Margin is 88.92%, with a median of 88.4% in 2024.
  • Its Gross Margin has fluctuated over the past 5 years, first tumbled by -141100bps in 2023, then surged by 36300bps in 2024.
  • Quarter analysis of 5 years shows Tg Therapeutics' Gross Margin stood at 82.47% in 2021, then grew by 17bps to 96.25% in 2022, then dropped by -15bps to 82.14% in 2023, then rose by 4bps to 85.77% in 2024, then decreased by -4bps to 82.63% in 2025.
  • Its Gross Margin was 82.63% in Q3 2025, compared to 86.58% in Q2 2025 and 87.14% in Q1 2025.